Dexcom Analyst Day Overview

Dexcom hosted its first ever Analyst Day and provided updates across its business including the company’s strategy to expand its market opportunity to non-intensive T2DM, gestational diabetes, and CGM use in hospitals. Of note, Dexcom displayed a picture of the fully disposable second generation Verily CGM which is being positioned as the product that will allow Dexcom to enter the non-intensively managed T2DM market. Below, FENIX provides an overview of the Analyst Day as well as thoughts on Dexcom’s pipeline activities and commercial opportunity. Pipeline Roadmap Dexcom senior management provided an overview of its pipeline activities including device integrations, predictive……

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.